Optimer Said to Draw Takeover Interest From Glaxo
This article is for subscribers only.
Optimer Pharmaceuticals Inc., the antibiotics maker that’s weighing a sale, drew interest from drugmakers including GlaxoSmithKline Plc and Japan’s Astellas Pharma Inc., said two people familiar with the matter. The shares gained the most in more than four years.
The maker of the antibiotic Dificid aims to fetch as much as $1 billion in a possible auction, said the people, who asked not to be named because the process is private. Optimer also attracted interest from Cubist Pharmaceuticals Inc. and AstraZeneca Plc, said one of the people.